Editing Genentech (section)

{{Short description|American biotechnology corporation}}
{{Use mdy dates|date=July 2020}}
{{Infobox company
| name = Genentech, Inc.
| logo = [[Image:Genentech.svg|210px]]
| type = [[Subsidiary]]
| traded_as = {{NASDAQ was|DNA}}
| foundation = {{start date and age|1976}}
| founders =[[Robert A. Swanson]] and [[Herbert Boyer]]
| location = [[South San Francisco, California|South San Francisco]], [[California]], United States
| key_people = {{unbulleted list| Ashley Magargee |(interim [[chief executive officer|CEO]])<ref>{{cite web |title=DEPARTURE OF ALEXANDER HARDY & APPOINTMENT OF ASHLEY MAGARGEE AS INTERIM CHIEF EXECUTIVE OFFICER GENENTECH |url=https://www.gene.com/media/statements/ps_110123 |website=Genentech |access-date=3 November 2023}}</ref>|Ed Harrington|[[Levi Garraway]]|Stephen Williams|Sean Johnston|[[Severin Schwan]]|([[chairman]] of Genentech Board of Directors, CEO of Roche Group)|Anna Batt|[[Aviv Regev]]<ref name="fiercebiotech"/><ref name="Press_Regev"/>}}
| industry = [[Biotechnology]]
| products = [[Avastin]], [[Herceptin]], [[Rituxan]], [[Perjeta]], [[Kadcyla]], [[Gazyva]], [[Tarceva]], [[Ocrelizumab|Ocrevus]], [[Polatuzumab vedotin|Polivy]], [[Atezolizumab|Tecentriq]], [[Baloxavir marboxil|Xofluza]], [[Emicizumab|Hemlibra]], [[Venetoclax|Venclexta]], [[Esbriet]], [[Cobimetinib|Cotellic]], [[Alecensa]], [[Zelboraf]], [[Nutropin]], [[Tocilizumab|Actemra]], [[Lucentis]], [[Xolair]], [[Alteplase|Activase]], [[Cathflo Activase]], [[Xeloda]], [[Boniva (drug)|Boniva]], [[TNKase]], [[CellCept]], [[Peginterferon alfa-2a|Pegasys]], [[Pulmozyme]], [[Tamiflu]], [[Valcyte]], [[Anaprox]], [[Cytovene]], [[Naproxen|EC-Naprosyn]], [[Erivedge]], [[Fuzeon]], [[Invirase]], [[Klonopin]], [[Kytril]], [[Naprosyn]], [[Rocephin]], Roferon-A, [[Romazicon]], [[Valium]], [[Xenical]], [[Zenapax]]
| num_employees = 13,539 (July 2021)
| revenue = {{Increase}} $26.4 billion (2020)<ref>{{cite web | url=https://fortune.com/best-workplaces-biotechnology-pharmaceuticals/2021/genentech/ | title=Genentech }}</ref>
| parent = [[Roche]]
| homepage = {{URL|gene.com}}
| footnotes = <ref>{{cite web|url=https://www.sec.gov/Archives/edgar/data/318771/000031877109000003/0000318771-09-000003.txt|title=FORM 10-K}}</ref>
}}
'''Genentech, Inc.''' is an American [[biotechnology]] [[corporation]] headquartered in [[South San Francisco, California]]. It operates as an independent [[subsidiary]] of holding company [[Roche]]. Genentech Research and Early Development operates as an independent center within Roche.<ref>{{cite web|url=http://www.gene.com/about-us|title=About Us|website=Gene.com|access-date=August 22, 2014|archive-url=https://web.archive.org/web/20140804185741/http://www.gene.com/about-us|archive-date=August 4, 2014|url-status=live}}</ref> Historically, the company is regarded as the world's first [[biotechnology]] company.<ref>{{cite journal |last1=Russo |first1=Eugene |title=Special Report: The birth of biotechnology |journal=Nature |date=January 2003 |volume=421 |issue=6921 |pages=456–457 |doi=10.1038/nj6921-456a |pmid=12540923 |bibcode=2003Natur.421..456R |s2cid=4357773 |doi-access=free }}</ref>

As of July 2021, Genentech employed 13,539 people.<ref>{{cite news |url=https://www.greatplacetowork.com/certified-company/1000096|title=Working at Genentech|website=Great Place to Work|language=en-US|access-date=November 18, 2021}}</ref>